JP2015520152A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520152A5
JP2015520152A5 JP2015511772A JP2015511772A JP2015520152A5 JP 2015520152 A5 JP2015520152 A5 JP 2015520152A5 JP 2015511772 A JP2015511772 A JP 2015511772A JP 2015511772 A JP2015511772 A JP 2015511772A JP 2015520152 A5 JP2015520152 A5 JP 2015520152A5
Authority
JP
Japan
Prior art keywords
aryl
membered heterocyclyl
membered
alkyl
carbazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511772A
Other languages
English (en)
Japanese (ja)
Other versions
JP6377054B2 (ja
JP2015520152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040604 external-priority patent/WO2013170186A1/en
Publication of JP2015520152A publication Critical patent/JP2015520152A/ja
Publication of JP2015520152A5 publication Critical patent/JP2015520152A5/ja
Application granted granted Critical
Publication of JP6377054B2 publication Critical patent/JP6377054B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511772A 2012-05-11 2013-05-10 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド Expired - Fee Related JP6377054B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645918P 2012-05-11 2012-05-11
US61/645,918 2012-05-11
US201361778176P 2013-03-12 2013-03-12
US61/778,176 2013-03-12
PCT/US2013/040604 WO2013170186A1 (en) 2012-05-11 2013-05-10 Carbazole-containing sulfonamides as cryptochrome modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017140820A Division JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Publications (3)

Publication Number Publication Date
JP2015520152A JP2015520152A (ja) 2015-07-16
JP2015520152A5 true JP2015520152A5 (enExample) 2017-02-09
JP6377054B2 JP6377054B2 (ja) 2018-08-22

Family

ID=48444649

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015511772A Expired - Fee Related JP6377054B2 (ja) 2012-05-11 2013-05-10 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2017140820A Withdrawn JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2019015689A Withdrawn JP2019077722A (ja) 2012-05-11 2019-01-31 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2020159390A Withdrawn JP2020203948A (ja) 2012-05-11 2020-09-24 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2022166167A Pending JP2023002659A (ja) 2012-05-11 2022-10-17 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017140820A Withdrawn JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2019015689A Withdrawn JP2019077722A (ja) 2012-05-11 2019-01-31 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2020159390A Withdrawn JP2020203948A (ja) 2012-05-11 2020-09-24 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2022166167A Pending JP2023002659A (ja) 2012-05-11 2022-10-17 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Country Status (15)

Country Link
US (3) US9265772B2 (enExample)
EP (1) EP2855458B1 (enExample)
JP (5) JP6377054B2 (enExample)
KR (1) KR102136431B1 (enExample)
CN (2) CN104640856B (enExample)
AR (1) AR092319A1 (enExample)
AU (1) AU2013259294B2 (enExample)
CA (1) CA2873214C (enExample)
IL (1) IL235602A0 (enExample)
MX (1) MX361457B (enExample)
NZ (2) NZ728724A (enExample)
RU (1) RU2654484C1 (enExample)
SG (1) SG11201407402TA (enExample)
TW (2) TWI643845B (enExample)
WO (1) WO2013170186A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728724A (en) * 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
CN105814071A (zh) * 2013-12-13 2016-07-27 阿勒根公司 类固醇样化合物的多晶型物及其制备和使用方法
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
KR101542324B1 (ko) * 2014-04-09 2015-08-05 동아대학교 산학협력단 손상된 dna의 회복 속도 비교를 위한 정보 제공 방법
EP3152185B1 (en) * 2014-06-04 2023-10-04 Roche Diagnostics GmbH Method and usage of a salt for separating epimers by ion mobility spectrometry
KR102422862B1 (ko) * 2016-07-04 2022-07-19 바이엘 크롭사이언스 악티엔게젤샤프트 벤조술탐 및 유사체, 및 살진균제로서의 이들의 용도
CN107941976B (zh) * 2017-09-28 2019-11-19 浙江新化化工股份有限公司 一种2-甲氧基环己胺的含量测定方法
JP7187152B2 (ja) * 2018-01-12 2022-12-12 三星電子株式会社 化合物、有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子用組成物、有機エレクトロルミネッセンス素子、及び化合物の製造方法
EP3836923B1 (en) * 2018-08-14 2024-10-16 OssiFi Therapeutics LLC Pyrrolo - dipyridine compounds for the treatment of bone loss
US20220081433A1 (en) * 2018-09-05 2022-03-17 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
CN109232596B (zh) * 2018-09-05 2020-03-17 大连九信精细化工有限公司 一种二苯并呋喃咔唑的合成方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114854803A (zh) * 2022-04-21 2022-08-05 山东农业大学 镰刀菌对3,6-二氯咔唑生物降解的方法
CN115974763B (zh) * 2022-12-26 2025-03-11 常州大学 一种咔唑衍生物及其应用
CN116217467B (zh) * 2023-03-09 2026-03-10 烟台皓元生物医药科技有限公司 一种erdrp-0519的中间体及其制备方法
WO2025183207A1 (ja) * 2024-02-28 2025-09-04 国立大学法人京都大学 がん免疫を活性化するスペルミジン誘導体
WO2025239319A1 (ja) * 2024-05-13 2025-11-20 国立大学法人東海国立大学機構 概日時計タンパク質cryに作用するフェニルピラゾール骨格を有する化合物を含有する経粘膜摂取剤

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4325952A (en) 1978-04-18 1982-04-20 Aziende Chimiche Riunite Angelini Francesco Method of treating abstinence syndrome with cycloaklyltriazoles
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4276890A (en) 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US4780401A (en) 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US4786653A (en) 1987-08-24 1988-11-22 Golwyn Daniel H Treatment of neurotransmitter-linked drug abuse
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
DE4004820A1 (de) 1989-08-05 1991-04-25 Bayer Ag Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5750015A (en) 1990-02-28 1998-05-12 Soane Biosciences Method and device for moving molecules by the application of a plurality of electrical fields
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5801155A (en) 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
KR20020005648A (ko) * 1999-04-01 2002-01-17 야마모토 카즈모토 삼환성 아미노알콜 유도체의 아지드를 경유하는 제조법
US6475744B1 (en) * 1999-07-22 2002-11-05 The General Hospital Corporation Methods for identifying compounds which modulate circadian rhythm
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
EP1238973A4 (en) * 1999-12-16 2003-01-22 Asahi Chemical Ind NEW SUBSTITUTED TRICYCLIC COMPOUNDS
WO2002006829A2 (en) 2000-07-18 2002-01-24 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
WO2003031031A1 (en) 2000-11-16 2003-04-17 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US7026343B2 (en) 2002-06-12 2006-04-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pharmacologic inhibition of Myc function
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
WO2004088309A2 (en) 2003-03-28 2004-10-14 Cantata Laboratories, Inc. Methods for diagnosing urinary tract and prostatic disorders
US20090163454A1 (en) 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
US7280776B2 (en) 2003-08-25 2007-10-09 Lexmark International, Inc. Method and apparatus to control waste toner collection in an image forming apparatus
JP4705630B2 (ja) * 2004-03-26 2011-06-22 エフ.ホフマン−ラ ロシュ アーゲー テトラヒドロカルバゾール及び誘導体
ES2334927T3 (es) * 2004-08-19 2010-03-17 Aventis Pharmaceuticals Inc. Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i.
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセット輸送体の調節剤
CL2007003591A1 (es) 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari
CA2681934A1 (en) * 2007-03-28 2008-10-02 High Point Pharmaceuticals, Llc 11beta-hsd1 active compounds
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US9095572B2 (en) * 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2748813C (en) 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2012009372A2 (en) 2010-07-12 2012-01-19 Colorado State University Research Foundation Triazolium carbene catalysts and processes for asymmetric carbon-carbon bond formation
NZ728724A (en) 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
WO2014031125A1 (en) * 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2014039515A2 (en) 2012-09-04 2014-03-13 University Of Massachusetts Antifungal agents and uses thereof
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
WO2015050984A1 (en) 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類

Similar Documents

Publication Publication Date Title
JP6650008B2 (ja) Ask1阻害剤の固体形態
US11161831B2 (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
Rammohan et al. A gist of gastrointestinal stromal tumors: A review
Swartz et al. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review
WO2020010118A1 (en) Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
Wei et al. Lactate-induced macrophage HMGB1 lactylation promotes neutrophil extracellular trap formation in sepsis-associated acute kidney injury
Boeckx et al. Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
JP2017099394A (ja) ヘッジホッグ阻害剤療法のためのバイオマーカー
JPWO2017014170A1 (ja) 複素環化合物
JP2013541339A5 (enExample)
Jegapragasan et al. A case of tophaceous gout in the lumbar spine: a review of the literature and treatment recommendations
JP2018530608A5 (enExample)
El Hoss et al. Precision medicine and sickle cell disease
Wettersten et al. Potential biofluid markers and treatment targets for renal cell carcinoma
WO2017192973A1 (en) Methods of treating cancers with gpr132 inhibitors
TW202535399A (zh) 用於治療實性瘤之方法與包含 krasg12c 抑制劑及 vegf 抑制劑之組成物
JP2012502962A5 (enExample)
JP6837632B2 (ja) 体液試料の単位量当たりのセルフリーdna量を健康状態の評価のための指標とする方法
CN117042763A (zh) 炎性疾病的治疗
Leng et al. Blocking TRAIL-DR5 signaling with soluble DR5 alleviates acute kidney injury in a severely burned mouse model
Karcz et al. [OP. 4B. 06] FREQUENCY OF PRIMARY ALDOSTERONISM IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA–OSA-PA STUDY
JP2018535997A5 (enExample)
WO2022255900A1 (ru) Лиганды цистеинил- лейкотриеновых рецепторов, направленные на терапию воспалительных и онкологических заболеваний
JP2016537327A5 (enExample)
Weiss et al. Activation of PPARγ by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats